FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310127386> ?p ?o ?g. }

• W4310127386 endingPage "1097" @default.
• W4310127386 startingPage "1095" @default.
• W4310127386 abstract "Prior studies by our group and others have demonstrated that platelets from patients with myeloproliferative neoplasms (MPNs) exhibit a hyperreactive phenotype. However, a complete understanding of platelet alterations in MPNs remains lacking, and the mechanisms by which platelets contribute to MPN-related thrombosis, as well as other MPN disease features, are incompletely understood. In this study, utilizing multiomic approaches to interrogate platelet phenotypes in patient samples, in conjunction with relevant MPN animal models (Figure 1A), we aim to investigate mechanisms of dysregulated platelet activity in MPNs, and explore how these findings may be leveraged to uncover novel therapeutic strategies. We initially studied platelet activation in peripheral blood from patients with essential thromobocythemia (ET) and compared to age-, sex-matched healthy controls. We found significantly increased P-selectin exposure in conjunction with increased platelet-leukocyte aggregates indicating activation of platelets from ET patients. To investigate the transcriptional signature of PBMCs and platelets at the single cell level, we performed single cell RNA-seq (scRNA-seq) in PBMCs from ET patients and healthy controls. Monocytes were increased in ET patients and displayed the highest inflammation index, implicating monocytes as the primary source of inflammation in ET. GSEA analysis revealed enrichment of platelet activation and oxidative phosphorylation (OXPHOS) genes in platelets from ET patients. Liquid chromatography-mass spectrometry (LC-MS) metabolomics analysis showed distinct metabolic phenotypes consisting of elevated tricarboxylic acid (TCA) cycle components, ATP generation and lower alpha-ketoglutarate (α-KG), in platelets from ET patients, all consistent with increased OXPHOS. α-KG is a key TCA cycle intermediate, which inhibits ATP generation via the suppression of ATP synthase. Extracellular flux analysis by Seahorse analysis confirmed bioenergetic alterations in MPN patient platelets. Enhanced mitochondrial respiration at both baseline and after ex vivo stimulation with the platelet agonist thrombin receptor activator peptide (TRAP6) was also observed from MPN patient platelets. Notably, α-KG supplementation drastically reduced oxygen consumption and ATP generation in platelets from MPN patients. We further investigated the effects of α-KG on MPN platelet activation. Ex vivo incubation of platelets from both MPN patients and Jak2 V617F knock-in mice with α-KG significantly reduced platelet surface P-selectin and integrin a2bb3 activation. Additionally, α-KG inhibited the spreading and adhesion of platelets from Jak2 V617F knock-in mice to fibrinogen-coated surfaces. Platelet phosphoblots demonstrated significant downregulation of p-STAT3, p-AKT and p-ERK after treatment with α-KG, suggesting these signaling pathways may be responsible for the inhibitory effects of α-KG on platelet activation. Thus, α-KG inhibited platelet activities in both human and mouse MPN samples. To test the therapeutic impact of α-KG on MPN disease features, we treated Jak2 V617F knock-in mice with α-KG for 6 weeks. Oral α-KG supplementation decreased splenomegaly and reduced elevated platelets and hematocrit. Additionally, monocytes were significantly decreased as early as 2 weeks after α-KG treatment in Jak2 V617F knock-in mice. In ex vivo studies with MPN patient CD34+ cells, α-KG treatment for 10 days led to a decrease in CD41+ CD61+ cells, suggesting decreased megakaryocyte commitment. We further observed that α-KG incubation significantly decreased the secretion of proinflammatory cytokines from sorted CD14+ human monocytes. Mass cytometry analysis of whole blood from MPN patients demonstrated inhibition of MAPK pathway signaling after α-KG treatment. Taken together, these results suggest that α-KG supplementation may exert therapeutic effects through both direct inhibition of MPN platelet activity and via quenching of monocyte hyper-inflammation (Figure 1B). In summary, these studies reveal a previously unrecognized metabolic disorder in platelets from MPN patients and highlight a prominent role for α-KG in aberrant MPN platelet activity and monocyte-driven inflammation. These findings have potential relevance for novel therapeutic approaches for MPN patients. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310127386 created "2022-11-30" @default.
• W4310127386 creator A5001251736 @default.
• W4310127386 creator A5002223712 @default.
• W4310127386 creator A5002632381 @default.
• W4310127386 creator A5011310207 @default.
• W4310127386 creator A5012179828 @default.
• W4310127386 creator A5022590189 @default.
• W4310127386 creator A5030093077 @default.
• W4310127386 creator A5045175167 @default.
• W4310127386 creator A5057876965 @default.
• W4310127386 creator A5062241525 @default.
• W4310127386 creator A5062562728 @default.
• W4310127386 creator A5064453044 @default.
• W4310127386 creator A5065778396 @default.
• W4310127386 creator A5072276577 @default.
• W4310127386 date "2022-11-15" @default.
• W4310127386 modified "2023-10-12" @default.
• W4310127386 title "Transcriptional and Metabolic Profiling Reveals Alpha-Ketoglutarate As a Novel Mediator of Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms" @default.
• W4310127386 doi "https://doi.org/10.1182/blood-2022-167786" @default.
• W4310127386 hasPublicationYear "2022" @default.
• W4310127386 type Work @default.
• W4310127386 citedByCount "0" @default.
• W4310127386 crossrefType "journal-article" @default.
• W4310127386 hasAuthorship W4310127386A5001251736 @default.
• W4310127386 hasAuthorship W4310127386A5002223712 @default.
• W4310127386 hasAuthorship W4310127386A5002632381 @default.
• W4310127386 hasAuthorship W4310127386A5011310207 @default.
• W4310127386 hasAuthorship W4310127386A5012179828 @default.
• W4310127386 hasAuthorship W4310127386A5022590189 @default.
• W4310127386 hasAuthorship W4310127386A5030093077 @default.
• W4310127386 hasAuthorship W4310127386A5045175167 @default.
• W4310127386 hasAuthorship W4310127386A5057876965 @default.
• W4310127386 hasAuthorship W4310127386A5062241525 @default.
• W4310127386 hasAuthorship W4310127386A5062562728 @default.
• W4310127386 hasAuthorship W4310127386A5064453044 @default.
• W4310127386 hasAuthorship W4310127386A5065778396 @default.
• W4310127386 hasAuthorship W4310127386A5072276577 @default.
• W4310127386 hasBestOaLocation W43101273861 @default.
• W4310127386 hasConcept C181199279 @default.
• W4310127386 hasConcept C203014093 @default.
• W4310127386 hasConcept C2107291 @default.
• W4310127386 hasConcept C2776914184 @default.
• W4310127386 hasConcept C2910274570 @default.
• W4310127386 hasConcept C2910453370 @default.
• W4310127386 hasConcept C502942594 @default.
• W4310127386 hasConcept C55493867 @default.
• W4310127386 hasConcept C60644358 @default.
• W4310127386 hasConcept C86803240 @default.
• W4310127386 hasConcept C89560881 @default.
• W4310127386 hasConcept C95444343 @default.
• W4310127386 hasConceptScore W4310127386C181199279 @default.
• W4310127386 hasConceptScore W4310127386C203014093 @default.
• W4310127386 hasConceptScore W4310127386C2107291 @default.
• W4310127386 hasConceptScore W4310127386C2776914184 @default.
• W4310127386 hasConceptScore W4310127386C2910274570 @default.
• W4310127386 hasConceptScore W4310127386C2910453370 @default.
• W4310127386 hasConceptScore W4310127386C502942594 @default.
• W4310127386 hasConceptScore W4310127386C55493867 @default.
• W4310127386 hasConceptScore W4310127386C60644358 @default.
• W4310127386 hasConceptScore W4310127386C86803240 @default.
• W4310127386 hasConceptScore W4310127386C89560881 @default.
• W4310127386 hasConceptScore W4310127386C95444343 @default.
• W4310127386 hasIssue "Supplement 1" @default.
• W4310127386 hasLocation W43101273861 @default.
• W4310127386 hasOpenAccess W4310127386 @default.
• W4310127386 hasPrimaryLocation W43101273861 @default.
• W4310127386 hasRelatedWork W2044199924 @default.
• W4310127386 hasRelatedWork W2116489286 @default.
• W4310127386 hasRelatedWork W2123410957 @default.
• W4310127386 hasRelatedWork W2412109466 @default.
• W4310127386 hasRelatedWork W2560939303 @default.
• W4310127386 hasRelatedWork W2561930967 @default.
• W4310127386 hasRelatedWork W2563181144 @default.
• W4310127386 hasRelatedWork W3211024713 @default.
• W4310127386 hasRelatedWork W3215660115 @default.
• W4310127386 hasRelatedWork W4309606996 @default.
• W4310127386 hasVolume "140" @default.
• W4310127386 isParatext "false" @default.
• W4310127386 isRetracted "false" @default.
• W4310127386 workType "article" @default.